At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 35 enrolled
Drug / intervention
dexfadrostat phosphatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
DP13 - A Phase II Study in Patients With Primary Aldosteronism to Evaluate the Efficacy, Safety and Tolerability of DP13, Over an 8-week Treatment Period
In Brief
A Phase 2 clinical trial evaluating dexfadrostat phosphate for Primary Aldosteronism. Completed, enrolled 35 participants across 1 site.
Detailed Summary
The purpose of the present phase II study is to determine whether DP13 displays the clinical safety and efficacy profile to support further development in patients with primary aldosteronism.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Aldosteronism
CountriesItaly
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedJul 2019
Enrollment StartNov 2019
Primary CompletionMay 2022
TodayJul 2026
First PostedJul 5, 2019
Enrollment StartNov 21, 2019
Primary CompletionMay 2, 2022
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 7.0 years ago
Interventions
dexfadrostat phosphatedrug
DP13 systemic administration